Search
News
Marathon Petroleum Q2 2026 earnings: Refining margins drive profit growth
Marathon Petroleum's Q2 2026 revenue rose 53.8% to $51.99 billion, diluted EPS increased to $17.73 from $3.96, and adjusted EBITDA reached $8.46 billion. The main driver was Refining & Marketing margin expansion to $36.33 per barrel as crack spreads improved across all regions, more than offsetting lower throughput and higher unit operating costs. Midstream EBITDA advanced modestly, while Renewable Diesel swung to a $258 million adjusted EBITDA profit. MPC ended June with $7.77 billion in cash and returned over $2.8 billion to shareholders.
TradingKey
Wed, Aug 5
Revvity Q2 2026 earnings: Diagnostics and tariff refunds lift adjusted margins
Revvity’s second-quarter 2026 revenue rose about 1% to $730 million, while GAAP EPS from continuing operations increased to $0.48 from $0.47. Adjusted EPS advanced to $1.41 and adjusted operating margin reached 28.9%, aided by $16 million of tariff refunds and stronger Diagnostics profitability. Diagnostics delivered 11% pro forma organic growth, offsetting a 3% decline in Life Sciences. Quarterly operating cash flow increased to $191.9 million, and Revvity raised its pro forma full-year guidance while excluding its planned China Immunodiagnostics divestiture.
TradingKey
Wed, Aug 5
Pediatrix Q2 2026 earnings: Reimbursement gains offset volume declines
Pediatrix Medical Group’s Q2 2026 net revenue rose 4.0% to $487.8 million, and diluted GAAP EPS increased to $0.49 from $0.46. Adjusted EBITDA advanced to $76.4 million, while cash from continuing operations declined to $126.3 million. Recent acquisitions and a 4.0% improvement in same-unit reimbursement factors offset a 2.1% drop in same-unit patient volume. Higher clinical, administrative, and restructuring costs pushed operating income lower, though the company reaffirmed its full-year adjusted EBITDA outlook of $280 million to $300 million.
TradingKey
Wed, Aug 5
ADM Q2 2026 earnings: Biofuel margins lift profit and guidance
ADM’s Q2 2026 results for the quarter ended June 30 featured net earnings of $908 million, diluted EPS of $1.87, and adjusted diluted EPS of $1.84, up 98% year over year. Total segment operating profit rose 75% to $1.45 billion, with gains across Ag Services & Oilseeds, Carbohydrate Solutions, and Nutrition. Better crushing and ethanol margins, supportive U.S. biofuel policy and Nutrition momentum drove the improvement. ADM raised full-year adjusted EPS guidance to $5.15-$5.60 from $4.15-$4.70.
TradingKey
Wed, Aug 5
Henry Schein Q2 2026 Earnings: Margin Gains Support Higher Guidance
Henry Schein’s Q2 2026 net sales increased 6.7% to $3.458 billion, including 4.6% internal growth, while GAAP diluted EPS rose to $0.82 from $0.70. Adjusted EBITDA reached $288 million, up 12.5%, and operating cash flow increased to $242 million. Organic momentum was strongest in Global Technology and dental merchandise, while wider margins and a lower diluted share count helped EPS grow faster than net income. Henry Schein raised FY2026 guidance to 4.5%-5.5% sales growth, $5.29-$5.39 in non-GAAP diluted EPS, and mid- to high-single-digit Adjusted EBITDA growth.
TradingKey
Wed, Aug 5
Qnity Q2 2026 earnings: Revenue rises 22% as GAAP profit falls
Qnity’s Q2 2026 net sales rose 22% year over year to $1.429 billion, while GAAP diluted EPS declined 34% to $0.59. Adjusted EPS increased 53% to $1.19 and adjusted operating EBITDA rose 24% to $431 million, as Interconnect Solutions grew 30% and Semiconductor Technologies grew 16%. Higher interest expense, transformation charges and other costs weighed on GAAP profit despite higher gross profit. Qnity also raised full-year 2026 guidance, including net sales of $5.55 billion to $5.65 billion and adjusted free cash flow of $600 million to $700 million.
TradingKey
Wed, Aug 5
Gartner Q2 2026 Earnings: EPS Rises 33.1% as Adjusted Revenue Grows 2.8%
Gartner’s Q2 2026 revenue declined 0.6% to $1.676 billion, but adjusted revenue excluding the divested Digital Markets operation rose 2.8%. GAAP diluted EPS increased 33.1% to $4.14, supported by 14.4% net income growth and a lower diluted share count. Free cash flow advanced 8.9% to $378 million. Operating income also increased about 15.7%, lifting the GAAP operating margin. Conferences grew 15.5%, Insights rose 2.1%, and Consulting fell 8.8%, while FX-neutral contract value increased 1.7% year over year.
TradingKey
Wed, Aug 5
Sequans Q2 2026 earnings: Product sales rise as gross margin contracts
Sequans Communications’ preliminary Q2 2026 results showed revenue of $7.5 million, down 8.4% year over year, while product sales rose 83.7%. Gross margin fell to 32.9% from 64.4% because the prior-year period benefited from Qualcomm license and services revenue and the current mix shifted toward products. The IFRS net loss widened to $9.8 million, although diluted loss per ADS narrowed to $0.65. Cash reached $21.0 million after Bitcoin sales helped fund the full redemption of convertible debt, while first-half operating cash outflow increased to $23.0 million.TradingKey
Wed, Aug 5
IDEAYA Q2 2026 earnings: Darovasertib NDA advances with $1.24 billion in cash
IDEAYA Biosciences’ Q2 2026 collaboration revenue rose sequentially to $8.9 million from $6.6 million, while net loss widened to $112.5 million as R&D and commercial-preparation costs increased. Cash, cash equivalents and marketable securities reached approximately $1.24 billion after June equity financing, supporting unchanged runway guidance into 2030. The main operating milestone was OptimUM-02’s positive progression-free survival result for the darovasertib combination, with an NDA submission underway through the FDA’s real-time oncology review program and several pipeline updates planned for the second half of 2026.
TradingKey
Wed, Aug 5
Leidos Q2 FY2026 Earnings: Revenue Rises as Margins Narrow
Leidos reported Q2 FY2026 revenue of $4.56 billion, up 7% year over year, while GAAP diluted EPS fell to $2.81 from $3.01. Adjusted EBITDA declined 2% to $631 million and its margin narrowed to 13.8%, but operating cash flow rose to $793 million and free cash flow reached $761 million. Homeland led segment growth, while lower medical disability exam volumes weighed on Health. Leidos also raised the low ends of its FY2026 revenue and non-GAAP EPS ranges and increased its operating cash flow outlook to approximately $1.85 billion.
TradingKey
Wed, Aug 5
Eve Q2 2026 earnings: Lower R&D narrows the net loss
Eve Holding’s Q2 2026 results showed a net loss of $34.2 million, down from $64.7 million a year earlier, as R&D expense fell to $28.9 million from $45.7 million. Quarterly cash consumption declined to $49.4 million, partly because some Embraer-related payments moved into Q3. Eve ended the quarter with $403.3 million in cash, cash equivalents and financial investments, while total liquidity reached $531.3 million. The pre-operational eVTOL developer expects full-year 2026 cash consumption of $250 million.TradingKey
Wed, Aug 5
Ball Q2 2026 Earnings: Shipments Rise as Operating Margin Narrows
Ball Corporation’s Q2 2026 revenue rose about 19.7% to $3.997 billion, comparable diluted EPS increased 14.4% to $1.03, and global aluminum packaging shipments grew 4.3%. Profit growth trailed sales as metal-linked pass-through pricing expanded revenue while North American operating and plant startup costs weighed on margins. South America delivered the largest regional earnings increase. Ball reiterated its 2026 goals, but negative first-half free cash flow means second-half cash conversion will be central to achieving the full-year target, while leverage has also increased from year-end.
TradingKey
Wed, Aug 5
DuPont Q2 2026 earnings: Adjusted EPS rises 48% on 4% sales growth
DuPont (NYSE: DD) reported second-quarter 2026 net sales of $1.819 billion, up 4% year over year, while adjusted EPS rose 48% to $1.88. Operating EBITDA increased 6% to $448 million and margin expanded 40 basis points to 24.6%, supported by organic growth and productivity. Continuing-operations cash flow also improved, with $400 million from operations and $326 million of transaction-adjusted free cash flow. The company raised full-year operating EBITDA and adjusted EPS guidance, citing strength in healthcare, industrial water and aerospace as support for its second-half outlook.
TradingKey
Wed, Aug 5
Waters Q2 2026 Earnings: Acquisition Doubles Revenue as GAAP Results Turn Negative
Waters' Q2 2026 revenue reached $1.645 billion, up 113% year over year after its Biosciences and Diagnostic Solutions acquisition, while organic revenue rose 7% reported and 9% in constant currency. The company posted a GAAP loss of $1.39 per share as acquisition-related amortization and fair-value step-ups weighed on reported earnings, but adjusted EPS increased 3% to $3.05. Operating cash flow improved to $200 million, and Waters raised full-year guidance to 7%-9% organic constant-currency growth and adjusted EPS of $14.45-$14.65 as end-market conditions broadened.
TradingKey
Wed, Aug 5
Wix Q2 2026 earnings: Revenue growth comes with weaker profitability
Wix.com’s Q2 2026 revenue rose 15% year over year to $563.1 million, while bookings increased 12% to $569.1 million. GAAP diluted EPS swung to a $1.78 loss from $0.98 in profit, and free cash flow fell to $52.6 million as operating expenses increased. Creative Subscriptions and Business Solutions revenue grew 15% and 14%, respectively. Wix maintained its full-year low- to mid-teens revenue growth outlook and expects Base44’s non-GAAP gross margin to reach about 60% in the second half as its proprietary AI model lowers compute costs.
TradingKey
Wed, Aug 5
FibroBiologics Q2 2026 Earnings: CYWC628 Dosing Begins With $3.5 Million in Cash
FibroBiologics (Nasdaq: FBLG) reported a Q2 2026 net loss of approximately $4.1 million, with R&D expense declining to $1.7 million from $2.0 million and G&A remaining about $2.4 million. Cash and equivalents totaled roughly $3.5 million at June 30. The quarter’s main operating development was the start of patient dosing in the Phase 1/2 CYWC628 diabetic foot ulcer trial. Interim results are targeted for the second half of 2026, while completed private and public financings provided additional capital and warrant exercises could generate up to approximately $6.0 million more.
TradingKey
Wed, Aug 5
CCEP H1 2026 results: Volume growth supports higher revenue
Coca-Cola Europacific Partners (CCEP) reported Q2 2026 revenue growth of 2.5% on a reported basis and 3.3% on an FX-neutral basis, with days-adjusted volume up 3.2%. For the six months ended July 3, 2026, reported revenue increased 4.4%, FX-neutral revenue rose 6.1%, and adjusted volume grew 2.2%. APS volume outpaced Europe, while water, sports, ready-to-drink tea and coffee, and energy-related categories led growth. Management cited continued margin expansion from efficiencies, reaffirmed full-year guidance, and flagged consumer, Middle East, and currency uncertainty.
TradingKey
Wed, Aug 5
Mohawk Industries Q2 2026 earnings: Tariff reimbursements amplify margin gains
Mohawk Industries’ Q2 fiscal 2026 net sales rose 6.8% to $2.99 billion, while GAAP diluted EPS increased to $3.22 from $2.34 and adjusted EPS reached $3.67. Adjusted operating margin expanded to 9.7% from 8.0%, supported by volume, pricing, mix, productivity and about $0.63 per share of tariff reimbursements. Free cash flow increased to $228.2 million. The company guided Q3 adjusted EPS to $2.50-$2.60, including roughly $0.12 of additional tariff reimbursements, as weak residential demand and higher input costs remain key pressures.
TradingKey
Wed, Aug 5
Mohawk Q2 2026 earnings: Profit rises with tariff refund support
Mohawk Industries’ Q2 2026 net sales rose 6.8% to $2.99 billion, while diluted EPS increased to $3.22 from $2.34 and adjusted EPS reached $3.67. The quarter included about $0.63 per share of tariff refunds, making that benefit important to the profit comparison. Free cash flow climbed to $228.2 million, and adjusted operating margin expanded to 9.7% from 8.0%. Global Ceramic and Flooring Rest of World posted adjusted sales growth, while Flooring North America declined 4.7% on an adjusted basis. Q3 baseline EPS guidance is $2.38 to $2.48.TradingKey
Wed, Aug 5
Iradimed Q2 2026 earnings: 3870 pump transition compresses margins
Iradimed reported Q2 2026 revenue of $20.5 million, up 0.5% year over year, while GAAP diluted EPS fell 9% to $0.41 and gross margin declined to 74% from 78%. The launch and production ramp of the new 3870 MRI-compatible IV pump weighed on pump revenue and manufacturing efficiency, even as patient-monitor, disposables, and ferromagnetic-detection sales increased. Operating cash flow fell 23% to $5.9 million, but free cash flow rose to $5.5 million as capital spending dropped. Management reaffirmed full-year 2026 revenue and EPS guidance.
TradingKey
Wed, Aug 5
Featured Tools
Top News
New CEO Ternus Launches iPhone 18 Pro on September 9 — Can Apple Reverse Q3 China Miss Before Jackson Hole?
Oracle Stock Forecast: $630 Billion AI Order Backlog Awaits Revaluation, Can the Stock Continue to Recover?
Micron vs. SK Hynix: As HBM Demand Continues to Surge, Which Memory Stock Deserves More Attention?
Cerebras Cloud Revenue Nearly Quadrupled — But Why Did the Stock Crash 17% on "Confusing" GAAP Results?
Western Digital Shares Plunge 50%: Is It the Best Time to Buy?
